Why Alnylam (ALNY) Might be Well Poised for a Surge

Core Insights - Alnylam Pharmaceuticals is experiencing solid improvement in earnings estimates, which may lead to continued stock price momentum [1][2] - Analysts are optimistic about the earnings prospects of Alnylam, driving higher estimates that correlate with stock price movements [2][3] Earnings Estimates - Current-quarter earnings estimate is $1.65 per share, reflecting a year-over-year increase of +430.0% [6] - The Zacks Consensus Estimate for the current quarter has risen by 20.29% over the last 30 days, with two estimates increasing and one decreasing [6] - For the full year, the earnings estimate is $3.81 per share, indicating a significant change of +19,150.0% from the previous year [7] - The consensus estimate for the current year has increased by 8.52% due to two upward revisions and no negative revisions [8] Zacks Rank - Alnylam currently holds a Zacks Rank 2 (Buy), indicating promising estimate revisions and potential for outperformance [9] - Stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) have historically outperformed the S&P 500 [9] Stock Performance - Alnylam's stock has increased by 6.2% over the past four weeks due to strong estimate revisions [10] - There may still be further upside potential in the stock, suggesting it could be a good addition to investment portfolios [10]